Southboro-based SynapDx Corp. said today it has received $6 million in funding from North Bridge Venture Partners and General Catalyst Partners for further development of a test designed to identify children with autism spectrum disorders by age 36 months.
The company said its blood-test approach measures differences in RNA gene expression to distinguish between children with a higher risk for ASDs from those without.
In its first phase, SynapDx obtained an exclusive license to recently published discoveries from Boston Children's Hospital. That study demonstrated the potential to identify more children with ASDs than other currently available tests, the company said.
"While one in 88 children in the U.S. are diagnosed with autism, only two in 10 are identified by age 36 months. The diagnostic journey is also long, expensive and confusing for families -- making this a clinically important but scientifically overlooked area of research," said SynapDx CEO Stanley Lapidus. "Our technology introduces an entirely new category of testing that has the potential to transform pediatrics and give parents and clinicians much-needed answers."
The company said it recently added Robert Carpenter, former executive vice president of Genzyme Corp., to its board of directors.
Anda sedang membaca artikel tentang
SynapDx raises $6M to develop blood test for autism disorders
Dengan url
http://terdiamtersipu.blogspot.com/2012/12/synapdx-raises-6m-to-develop-blood-test.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
SynapDx raises $6M to develop blood test for autism disorders
namun jangan lupa untuk meletakkan link
SynapDx raises $6M to develop blood test for autism disorders
sebagai sumbernya
0 komentar:
Posting Komentar